EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC 4.0

Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

Robert F Kushner iD, Donna H Ryan, John Deanfield, Alexander Kokkinos, Cintia Cercato, John Wilding, Bartolome Burguera iD, Chau-Chung Wu, Anca-Elena Craciun, Denes Pall, Irene Hramiak, Jøran Hjelmesæth and 6 more

Obesity · 2025-03 · 33 (3) · 452-462

DOI: 10.1002/oby.24222 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, published online on 2025-02-13. Written by Robert F Kushner and 17 co-authors. Institution: Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Major MEDLINE topics: Glucagon-Like Peptides, Cardiovascular Diseases, Obesity, Overweight. Cited 41 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIDDK NIH HHS, Novo Nordisk A/S.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

The objective of this study was to assess safety of once‐weekly subcutaneous semaglutide 2.4 mg versus placebo, beyond reduction in major adverse cardiovascular events, in patients with established cardiovascular disease and overweight or obesity.

Methods

Safety data focused on serious adverse events (SAEs), all adverse events (AEs) leading to permanent treatment discontinuation irrespective of seriousness, and prespecified AEs of special interest irrespective of seriousness. Tests of treatment differences were determined by two‐sided p values.

Results

The proportion of patients with SAEs was lower with semaglutide versus placebo (33.4% vs. 36.4%; p < 0.001), primarily driven by cardiac disorders (11.5% vs. 13.5%; p < 0.001). The proportion of patients with AEs leading to discontinuation was higher with semaglutide versus placebo (16.6% vs. 8.2%; p < 0.001), a difference driven by gastrointestinal disorders (10.0% vs. 2.0%); however, proportions due to SAEs leading to discontinuation were similar (3.6% vs. 4.1%). Suicide/self‐injury SAEs were low and balanced between groups (0.11% in both groups). Gallbladder‐related disorders were more frequent with semaglutide versus placebo (2.8% vs. 2.3%; p = 0.04), mainly driven by cholelithiasis (1.4% vs. 1.1%), whereas proportions of cholecystitis were similar between groups (0.6% vs. 0.6%).

Conclusions

The long‐term safety profile observed in the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) study is consistent with previously reported semaglutide studies. No new safety concerns were identified for once‐weekly semaglutide 2.4 mg.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like PeptidesCardiovascular DiseasesObesityOverweightHumansFemaleMaleMiddle AgedAdultDouble-Blind MethodAgedTreatment OutcomeInjections, SubcutaneousGastrointestinal DiseasesGlucagon-Like Peptide 1Semaglutide

Substances

Glucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Authors and institutions

  • Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
  • Institute of Cardiovascular Science, University College London, London, UK.
  • First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Obesity Unit, Department of Endocrinology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
  • Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.

ORCID profiles: Robert F Kushner, Bartolome Burguera, Ildiko Lingvay

Funding

  • NIDDK NIH HHS
  • Novo Nordisk A/S

Cite

APA

Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C. C., Craciun, A. E., Pall, D., Hramiak, I., Hjelmesæth, J., Harder-Lauridsen, N. M., Weimers, P., Jeppesen, O. K., Kallenbach, K., Lincoff, A. M., & Lingvay, I. (2025). Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity, 33(3), 452-462. https://doi.org/10.1002/oby.24222

Vancouver

Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity. 2025;33(3):452-462. doi:10.1002/oby.24222

BibTeX
@article{Kushner2025,
  author = {Kushner, Robert F and Ryan, Donna H and Deanfield, John and Kokkinos, Alexander and Cercato, Cintia and Wilding, John and Burguera, Bartolome and Wu, Chau-Chung and Craciun, Anca-Elena and Pall, Denes and Hramiak, Irene and Hjelmesæth, Jøran and Harder-Lauridsen, Nina M and Weimers, Petra and Jeppesen, Ole Kleist and Kallenbach, Klaus and Lincoff, A Michael and Lingvay, Ildiko},
  title = {Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {3},
  pages = {452--462},
  doi = {10.1002/oby.24222}
}
Start for free →